DrugPatentWatch Database Preview
Merck Sharp Dohme Company Profile
Email this page to a colleague
» See Plans and PricingUS Patents for Merck Sharp Dohme
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | ZINPLAVA | bezlotoxumab | INJECTABLE;INJECTION | 761046 | 001 | 2016-10-21 | 9,181,632 | MERCK SHARP & DOHME CORP. (Rahway, NJ) | 2033-09-09 | RX | search | |
| Merck Sharp Dohme | ZINPLAVA | bezlotoxumab | INJECTABLE;INJECTION | 761046 | 001 | 2016-10-21 | 10,590,182 | The Regents of the University of California (Oakland, CA) | 2035-02-24 | RX | search | |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 9,995,753 | Merck Sharp & Dohme Corp. (Rahway, NJ) | 2035-09-25 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 9,994,550 | 3-V Biosciences, Inc. (Menlo Park, CA) | 2034-01-07 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 9,975,894 | Plexxikon Inc. (Berkeley, CA) | 2035-09-21 | RX | Orphan | search |
| Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 9,968,606 | NeuForm Pharmaceuticals, Inc. (Auburndale, MA) | 2035-12-27 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Similar Applicant Names
Companies are sometimes listed under multiple names.
This search can help find similar names.
This search can help find similar names.
